The therapeutic effect of anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (nAMD) was determined by a number of factors. Comprehensive thorough analysis of clinical features, imaging results and treatment response can predict the potential efficacy and possible vision recovery for the patient, and also can optimize the treatment regime to make a personalized therapy plan. Precise medicine with data from genomics, proteomics and metabolomics study will provide more objective and accurate biology basis for individual precise treatment. The future research should focus on comprehensive assessment of factors affecting the efficacy of anti-VEGF therapy, to achieve individualized precise diagnosis and treatment, to improve the therapeutic outcome of nAMD.
ObjectiveTo observe the longterm effect of suramin on the inhibition of proliferation of human retinal pigment epithelial (RPE) cells in vitro. MethodsRPE cells grown in 9 pieces of 96well plate (12 wells each plate) were divided into experimental and control group, with 6 wells in each group. The concentration of 0.1 ml RPE cells in each well is 5×104 cells/ml. After the change of the medium, RPE cells were treated with suramin (250 μg/ml) in experimental group while treated with nothing in the control group. The medium of the 2 groups were changed to the normal medium after 4 days. At the 1st, 2nd, and 4thday after the addition of suramin and at the 1st, 2nd, 3rd, 5th, 6th, 7th, 9th , 11th and 13th day after removing suramin, 1 plate was randomly selected to stop culturing, and the proliferation of RPE cells were detected by methyl thiazolyl tetrazolium (MTT) assay. ResultsUnder reversed microscope, RPE cells in control group were fused completely at the 7th day after inoculation. The extracellular space of RPE cells in experimental groups was larger than that in the control group, and remained unfused at the 13th day after inoculation. The inhibitory rate of proliferation of RPE cells at the first day after treated with suramin was 14.85% and increased to the highest 25.79% at the 4th day. The first day after the suramincontaining media was removed, the inhibitory rate decreased to 12.35%, and then raised gradually to over 20% at the 3rd to 5th day. Finally, the rate drop to 14.71%. ConclusionSuramin has the long-term effect on the inhibition of RPE cells induced by serum, especially the inhibitive effect after the remove of suramin, which indicates the specific double-peak inhibition during the whole process.(Chin J Ocul Fundus Dis, 2005,21:25-27)
Objective To observe the effect of resveratrol on multidrug resistance (MDR) in human retinoblastoma cells treated. Methods RB cells in logarithmic growth phase were divided into experimental group and control group. RB cells in experimental group were cultured with different concentrations of resveratrol (6.25, 12.50, 25.00, 50.00, 100.00 mu;mol/L) for 24 and 48 hours. The proliferation (absorbance value) was assayed using methyl thiazolyl tetrazolium (MTT). RB cells were cultured with 50.00 mu;mol/L resveratrol for 48 hours. The expressions of MDR-1, cyclooxygenase-2 (COX-2)、multidrug resistance-associated protein-1 (MRP-1), glutathione-S-transferases-pi; (GST-pi;) were determined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot. The RB cells of the control group were cultured with 0.5% dimethyl sulfoxide. Results Compared with the control group, the absorbance value decreased in experimental groups (6.25, 12.50, 25.00, 50.00 mu;mol/L) in a dose dependent manner (F=4.782，P＜0.05). The difference of absorbance value between 50.00 and 100.00 mu;mol/L experimental groups was not significant (F=6.351,P＞0.05). Compared with the control group, the mRNA (t=9.170, 5.758, 4.152, 4.638) and protein (t=3.848, 5.955, 4.541, 3.514) expression levels of MDR-1, MRP1, COX-2, and GST-pi; decreased in the experimental group (P＜0.05). Conclusion Resveratrol can down-regulate the expression of MDR in RB cells.
Since anti-vascular endothelial growth factor (VEGF) therapy has recently become the first-line treatment of wet age related macular degeneration in China, as well as retinopathy of prematurity, neovascular glaucoma and macular edema secondary to diabetic retinopathy or retinal vein occlusion in other countries. It is worth thinking about that how to perform anti-VEGF treatment properly to benefit more patients. We reviewed the fields of clinical researches to explore the best role of anti-VEGF treatment in prevention and treatment of retinal disease in future.
Objective To observe in vitro the protective effect of cranial nerve growthine (CNG) on the optic nerve injured by acute ocular hypertension. Methods Thirty white rabbits were divided into five groups,and 6 in each.The acute ocular hypertension(50 mm Hg) models were established by forcing perfusion of normal saline solution into the anterior chamber sustained for 6 h in one eye,and the contral ateral eye of each rabbit was regard as control.Three rabbits in each group were then treated by CNG 0.2 ml intramuscularly every day.The optic nerve and retina was surgically removed at five different time points (lst,3rd,7th,15th and 30th day) after operation.With the HRP orthograde tracing technique and transmitted electron microscope,the effect of CNG on the optic nerve was observed by the changes of axonal transport and ultrastructure of optic nerve. Results Compare with experimental control groups (25.17plusmn;1.03),HRP reactive products of treated groups (39.79plusmn;2.29) markedly increased after seven days (Plt;0.01).The degeneration of axons in treated groups was relatively lighter after fifteen days and some axons recovered after thirty days. Conclusion CNG might improve the axonal transport and the recovery of axons after the optic nerve injured by acute ocular hypertension. (Chin J Ocul Fundus Dis,2000,16:88-90)
Serpiginous choroiditis (SC) is infrequent, chronic and posterior uveitis displaying a geographic pattern of choroiditis easy to recur. Studies reveal that the active lesions of inflammatory processes are mainly localized to the choriocapillaris and retinal pigment epithelium cells. SC may manifest with variable features, although a creeping pattern of choroiditis, extending from the juxtapapillary area, with grayish yellow discoloration. Fundus fluorescein angiography, indocyanine green angiography, fundus auto-fluorescence and optical coherence tomography are helpful to diagnose atypical SC. In addition, these image examinations can evaluate the activity and progression of lesion, and detect any complication that might occur. SC is mainly distinguished from multifocal SC related with tuberculosis or virus and etc. Pathogenesis is unclear, an organ-specific autoimmune inflammation or infection seems likely to be the underlying process. It is mainly using glucocorticoid with immunosuppressant therapy at present. Timely and effectively control inflammation can effectively prevent vision loss, choroidal neovascularization and choroidal scar in SC patients.
Atrial fibrillation, as the most common arrhythmia currently, can lead to secondary post-stroke cognitive dysfunction and chronic brain damage through various pathways, increasing the risk of cognitive dysfunction and affecting patient prognosis. The prevention and treatment drugs for cognitive dysfunction associated with atrial fibrillation mainly include anticoagulants, heart rhythm and heart rate control drugs, statins, and antihypertensive drugs. At present, there is still some controversy over the medication for cognitive dysfunction associated with atrial fibrillation, lacking guidelines and expert consensus. It is urgent and necessary to find safe, economical, and effective drugs to improve the cognitive function of atrial fibrillation patients. This article summarizes the recent advances in drug therapy for cognitive dysfunction associated with atrial fibrillation, in order to provide a reference for the treatment of cognitive dysfunction associated with atrial fibrillation in clinical practice.
ObjectiveTo observe the clinical features of bacillary layer detachment (BALAD) in neovascular age-related macular degeneration (nAMD) and its response to anti-vascular endothelial growth factor (VEGF) therapy. MethodsA retrospective clinical study. From July 2019 to July 2024, 188 patients (188 eyes) with nAMD who were continuously admitted to Tianjin University Aier Eye Hospital and received anti-VEGF drug treatment were included in the study. All eyes underwent best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) examinations. Treatment consisted of intravitreal anti-VEGF injections monthly for 3 months, followed by a pro re nata regimen. Based on the presence of BALAD on baseline OCT, eyes were divided into a BALAD group and a control group. BCVA was measured using a standard logarithmic visual acuity chart and converted to the logarithm of the minimum angle of resolution; central retinal thickness (CRT) was measured by OCT. Patients were followed for ≥12 months. Differences in CRT, BCVA, macular neovascularization (MNV) subtypes, and treatment outcomes at 12 months were compared between the two groups. The Scheirer-Ray-Hare test was used for non-normally distributed repeated measures data to compare interactions between time and group for BCVA and CRT; Spearman's rank correlation was used for correlation analysis of continuous variables between groups. ResultsThe number of eyes in the BALAD group and the control group was 33 (17.55%, 33/188) and 155 (82.45%, 155/188) respectively. Among the 33 eyes in the BALAD group, 21 eyes (63.64%, 21/33) had type 1 MNV, among which 18 eyes had polypoid choroidal vascular disease (PCV). There was no statistically significant difference in the gender composition ratio and MNV classification between the two groups of patients (χ2=2.09, 1.87; P＞0.05). There were statistically significant differences in age (t=−2.63), the proportion of PCV (χ2=13.73), and CRT (Z=−3.03) (P＜0.05). Twelve months after treatment, the cystic cavities of 84.85% (28/33) of the affected eyes in the BALAD group subsided. The BCVA of both groups of affected eyes improved over time (H=17.93, P＜0.05), but the overall BCVA of the BALAD group was still worse than that of the control group (H=17.80, P＜0.05). There was a significant difference in the improvement degree of CRT between the two groups (H=43.87, P＜0.05), and only in the control group was a significant positive correlation between BCVA and CRT (r=0.24, P＜0.05). ConclusionsIn nAMD, BALAD is associated with type 1 MNV, particularly the PCV subtype, and may serve as a biomarker for predicting anti-VEGF response. Although the BALAD structure is sensitive to anti-VEGF therapy and readily resolves, the limited functional improvement suggests it may be an imaging indicator of poor prognosis.
ObjectiveTo evaluate the efficacy in the treatment of age-related macular degeneration (AMD) by bevacizumab versus ranibizumab. MethodsA computerized search was conducted in the Embase, Ovid, PubMed, China National Knowledge Infrastructure (CNKI), WanFang Data and VIP database of Chinese journal. Randomized controlled trials (RCTs) comparing bevacizumab with ranibizumab for AMD from inception to November, 2013 were collected. Methodology qualifies of studies were performed by experienced reviewers according to the inclusion and exclusion criteria. Further, the materials were analyzed with software RevMan 5.2.6. Visual acuity and central foveal thickness before and 3, 6, 12 months after treatment between the two treatment methods were compared. ResultsA total of 5 RCTs were included in this meta analysis, including 1954 patients (967 patients in the bevacizumab group, 987 eyes in the ranibizumab group). There was no difference in improving visual acuity after treatment between two groups [3 months: weighted mean difference (WMD)=0.32, 95% CI: -0.84 -1.49, P=0.59; 6 months: WMD=0.47, 95% CI: -0.67 -1.62, P=0.42; 12 months: WMD=0.84, 95% CI: -0.23 -1.90, P=0.12]. There was no difference in cutting down the central foveal thickness after treatment between two groups (3 months: WMD=6.21, 95% CI: -6.23-18.65, P=0.33; 6 months: WMD=4.06, 95% CI: -6.16-14.27, P=0.44; 12 months: WMD=-5.39, 95% CI: -14.41-3.63, P=0.24). ConclusionBevacizumab has equal efficacy to ranibizumab in the treatment of AMD.
For choroidal neovascularization (CNV) secondary to pathological myopia, intravitreal injection of anti-VEGF has been widely used in clinic and achieved good outcome. However, due to the differences in the demographic characteristics, stages of disease progression and treatment procedure of CNV, the prognosis of the disease is variable. Complete ellipsoid band, smaller baseline choroidal neovascularization and better baseline vision are important predictors of good outcome of anti-vascular endothelial growth factor treatment. Chorioretinal atrophy or complications related to pathologic myopia indicate a poor prognosis. The influence of age, race, previous photodynamic therapy and early treatment on the prognosis of treatment need to be further studied.